Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature

Summary Autoimmune myelofibrosis (AIMF) is a distinct clinicopathological entity associated with diffuse bone marrow fibrosis and a benign clinical course. Distinction from neoplastic etiologies of marrow fibrosis, particularly primary myelofibrosis, is imperative, but few studies have documented hi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2014-11, Vol.45 (11), p.2183-2191
Hauptverfasser: Vergara-Lluri, Maria E., MD, Piatek, Caroline I., MD, Pullarkat, Vinod, MD, Siddiqi, Imran N., MD, PhD, O'Connell, Casey, MD, Feinstein, Donald I., MD, Brynes, Russell K., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2191
container_issue 11
container_start_page 2183
container_title Human pathology
container_volume 45
creator Vergara-Lluri, Maria E., MD
Piatek, Caroline I., MD
Pullarkat, Vinod, MD
Siddiqi, Imran N., MD, PhD
O'Connell, Casey, MD
Feinstein, Donald I., MD
Brynes, Russell K., MD
description Summary Autoimmune myelofibrosis (AIMF) is a distinct clinicopathological entity associated with diffuse bone marrow fibrosis and a benign clinical course. Distinction from neoplastic etiologies of marrow fibrosis, particularly primary myelofibrosis, is imperative, but few studies have documented histopathologic features in a large series. We describe 29 patients with AIMF, defined as marrow reticulin fibrosis and lymphocytic infiltration in the context of an established autoimmune disorder (secondary AIMF) or autoantibodies without a defined disorder (primary AIMF). Excluded were cases with atypical megakaryocytes, dysplasia, basophilia, osteosclerosis, unexplained splenomegaly, or neoplasms associated with myelofibrosis (MF). All cases were stained for reticulin, CD3, and CD20, with a subset additionally stained for CD138, κ , λ , immunoglobulin G (IgG), and IgG4. Lymphoid aggregates, where present, were classified into T-cell and B-cell patterns of distribution. Most patients (93%) presented with cytopenias. Sixty-nine percent (n = 20) were considered secondary AIMF and the remainder primary AIMF (n = 9). Peripheral blood showed absent-to-rare blasts and teardrop erythrocytes and absence of eosinophilia or basophilia. Characteristic bone marrow findings included hypercellularity with erythroid and megakaryocytic hyperplasias, mild reticulin fibrosis, intrasinusoidal hematopoiesis, T-cell pattern in lymphoid aggregates, mild polytypic plasmacytosis, and absence of IgG4-positive plasma cells. Primary and secondary AIMF were pathologically indistinguishable, except for an increased incidence of granulocytic hyperplasia in primary AIMF. This series confirms and expands the utility of the original diagnostic criteria for AIMF. Recognizing the characteristic morphology of AIMF and its associated clinical and laboratory features distinguishes autoimmune from neoplastic causes of MF and guides further evaluation and management.
doi_str_mv 10.1016/j.humpath.2014.07.017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1654670894</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0046817714003153</els_id><sourcerecordid>1654670894</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-501aa3d4f7438490bbd235fc6d7292dccd07c6838566fa4680abc881873073943</originalsourceid><addsrcrecordid>eNqNkkuP1DAQhCMEYoeFnwCyxIVLQvsVOxxAqxUvaSUOwNny2B3GQxIPdgKaf4_DDCDtBU7uw9dlVVVX1WMKDQXaPt83u2U82HnXMKCiAdUAVXeqDZWc1Zp37G61ARBtralSF9WDnPcAlEoh71cXTDLNgKtN5a-WOYZxXCYk4xGH2IdtijnkF8ROZDl4OyOJExljOuziEL8ER3q085IwkzAR1hFnc5nt5EnC7wF_kNiTeYdkCDOmX-TD6l5vh4yPzu9l9fnN60_X7-qbD2_fX1_d1E52Yq4lUGu5F70SXIsOtlvPuOxd6xXrmHfOg3Kt5lq2bW9Fq8FundZUKw6Kd4JfVs9OuocUvy2YZzOG7HAY7IRxyYa2UrQK9H-hrOtUK_WKPr2F7uOSpmKkUFR0bI21UPJEuRJfTtibQwqjTUdDwayNmb05N2bWxgwoUxore0_O6st2RP9n63dFBXh1ArAkV_JNJruAk0MfErrZ-Bj--cXLWwpuCFNwdviKR8x_3ZjMDJiP69msV0MFAC_W-E9Zrr1n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1614920115</pqid></control><display><type>article</type><title>Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Vergara-Lluri, Maria E., MD ; Piatek, Caroline I., MD ; Pullarkat, Vinod, MD ; Siddiqi, Imran N., MD, PhD ; O'Connell, Casey, MD ; Feinstein, Donald I., MD ; Brynes, Russell K., MD</creator><creatorcontrib>Vergara-Lluri, Maria E., MD ; Piatek, Caroline I., MD ; Pullarkat, Vinod, MD ; Siddiqi, Imran N., MD, PhD ; O'Connell, Casey, MD ; Feinstein, Donald I., MD ; Brynes, Russell K., MD</creatorcontrib><description>Summary Autoimmune myelofibrosis (AIMF) is a distinct clinicopathological entity associated with diffuse bone marrow fibrosis and a benign clinical course. Distinction from neoplastic etiologies of marrow fibrosis, particularly primary myelofibrosis, is imperative, but few studies have documented histopathologic features in a large series. We describe 29 patients with AIMF, defined as marrow reticulin fibrosis and lymphocytic infiltration in the context of an established autoimmune disorder (secondary AIMF) or autoantibodies without a defined disorder (primary AIMF). Excluded were cases with atypical megakaryocytes, dysplasia, basophilia, osteosclerosis, unexplained splenomegaly, or neoplasms associated with myelofibrosis (MF). All cases were stained for reticulin, CD3, and CD20, with a subset additionally stained for CD138, κ , λ , immunoglobulin G (IgG), and IgG4. Lymphoid aggregates, where present, were classified into T-cell and B-cell patterns of distribution. Most patients (93%) presented with cytopenias. Sixty-nine percent (n = 20) were considered secondary AIMF and the remainder primary AIMF (n = 9). Peripheral blood showed absent-to-rare blasts and teardrop erythrocytes and absence of eosinophilia or basophilia. Characteristic bone marrow findings included hypercellularity with erythroid and megakaryocytic hyperplasias, mild reticulin fibrosis, intrasinusoidal hematopoiesis, T-cell pattern in lymphoid aggregates, mild polytypic plasmacytosis, and absence of IgG4-positive plasma cells. Primary and secondary AIMF were pathologically indistinguishable, except for an increased incidence of granulocytic hyperplasia in primary AIMF. This series confirms and expands the utility of the original diagnostic criteria for AIMF. Recognizing the characteristic morphology of AIMF and its associated clinical and laboratory features distinguishes autoimmune from neoplastic causes of MF and guides further evaluation and management.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2014.07.017</identifier><identifier>PMID: 25282037</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Autoimmune diseases ; Autoimmune Diseases - pathology ; Autoimmune disorders ; Autoimmune myelofibrosis ; Bone marrow ; Bone marrow fibrosis ; Disease ; Female ; Hepatitis ; Humans ; IgG4 related disease ; Immune system ; Lupus ; Lymphocytes ; Male ; Medical prognosis ; Metabolic disorders ; Middle Aged ; Morphologic criteria ; Non-neoplastic fibrosis ; Pathology ; Primary Myelofibrosis - pathology ; Transplants &amp; implants ; Tumors ; Young Adult</subject><ispartof>Human pathology, 2014-11, Vol.45 (11), p.2183-2191</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Nov 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-501aa3d4f7438490bbd235fc6d7292dccd07c6838566fa4680abc881873073943</citedby><cites>FETCH-LOGICAL-c594t-501aa3d4f7438490bbd235fc6d7292dccd07c6838566fa4680abc881873073943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.humpath.2014.07.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25282037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vergara-Lluri, Maria E., MD</creatorcontrib><creatorcontrib>Piatek, Caroline I., MD</creatorcontrib><creatorcontrib>Pullarkat, Vinod, MD</creatorcontrib><creatorcontrib>Siddiqi, Imran N., MD, PhD</creatorcontrib><creatorcontrib>O'Connell, Casey, MD</creatorcontrib><creatorcontrib>Feinstein, Donald I., MD</creatorcontrib><creatorcontrib>Brynes, Russell K., MD</creatorcontrib><title>Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Summary Autoimmune myelofibrosis (AIMF) is a distinct clinicopathological entity associated with diffuse bone marrow fibrosis and a benign clinical course. Distinction from neoplastic etiologies of marrow fibrosis, particularly primary myelofibrosis, is imperative, but few studies have documented histopathologic features in a large series. We describe 29 patients with AIMF, defined as marrow reticulin fibrosis and lymphocytic infiltration in the context of an established autoimmune disorder (secondary AIMF) or autoantibodies without a defined disorder (primary AIMF). Excluded were cases with atypical megakaryocytes, dysplasia, basophilia, osteosclerosis, unexplained splenomegaly, or neoplasms associated with myelofibrosis (MF). All cases were stained for reticulin, CD3, and CD20, with a subset additionally stained for CD138, κ , λ , immunoglobulin G (IgG), and IgG4. Lymphoid aggregates, where present, were classified into T-cell and B-cell patterns of distribution. Most patients (93%) presented with cytopenias. Sixty-nine percent (n = 20) were considered secondary AIMF and the remainder primary AIMF (n = 9). Peripheral blood showed absent-to-rare blasts and teardrop erythrocytes and absence of eosinophilia or basophilia. Characteristic bone marrow findings included hypercellularity with erythroid and megakaryocytic hyperplasias, mild reticulin fibrosis, intrasinusoidal hematopoiesis, T-cell pattern in lymphoid aggregates, mild polytypic plasmacytosis, and absence of IgG4-positive plasma cells. Primary and secondary AIMF were pathologically indistinguishable, except for an increased incidence of granulocytic hyperplasia in primary AIMF. This series confirms and expands the utility of the original diagnostic criteria for AIMF. Recognizing the characteristic morphology of AIMF and its associated clinical and laboratory features distinguishes autoimmune from neoplastic causes of MF and guides further evaluation and management.</description><subject>Adult</subject><subject>Aged</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - pathology</subject><subject>Autoimmune disorders</subject><subject>Autoimmune myelofibrosis</subject><subject>Bone marrow</subject><subject>Bone marrow fibrosis</subject><subject>Disease</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>IgG4 related disease</subject><subject>Immune system</subject><subject>Lupus</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metabolic disorders</subject><subject>Middle Aged</subject><subject>Morphologic criteria</subject><subject>Non-neoplastic fibrosis</subject><subject>Pathology</subject><subject>Primary Myelofibrosis - pathology</subject><subject>Transplants &amp; implants</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkuP1DAQhCMEYoeFnwCyxIVLQvsVOxxAqxUvaSUOwNny2B3GQxIPdgKaf4_DDCDtBU7uw9dlVVVX1WMKDQXaPt83u2U82HnXMKCiAdUAVXeqDZWc1Zp37G61ARBtralSF9WDnPcAlEoh71cXTDLNgKtN5a-WOYZxXCYk4xGH2IdtijnkF8ROZDl4OyOJExljOuziEL8ER3q085IwkzAR1hFnc5nt5EnC7wF_kNiTeYdkCDOmX-TD6l5vh4yPzu9l9fnN60_X7-qbD2_fX1_d1E52Yq4lUGu5F70SXIsOtlvPuOxd6xXrmHfOg3Kt5lq2bW9Fq8FundZUKw6Kd4JfVs9OuocUvy2YZzOG7HAY7IRxyYa2UrQK9H-hrOtUK_WKPr2F7uOSpmKkUFR0bI21UPJEuRJfTtibQwqjTUdDwayNmb05N2bWxgwoUxore0_O6st2RP9n63dFBXh1ArAkV_JNJruAk0MfErrZ-Bj--cXLWwpuCFNwdviKR8x_3ZjMDJiP69msV0MFAC_W-E9Zrr1n</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Vergara-Lluri, Maria E., MD</creator><creator>Piatek, Caroline I., MD</creator><creator>Pullarkat, Vinod, MD</creator><creator>Siddiqi, Imran N., MD, PhD</creator><creator>O'Connell, Casey, MD</creator><creator>Feinstein, Donald I., MD</creator><creator>Brynes, Russell K., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20141101</creationdate><title>Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature</title><author>Vergara-Lluri, Maria E., MD ; Piatek, Caroline I., MD ; Pullarkat, Vinod, MD ; Siddiqi, Imran N., MD, PhD ; O'Connell, Casey, MD ; Feinstein, Donald I., MD ; Brynes, Russell K., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-501aa3d4f7438490bbd235fc6d7292dccd07c6838566fa4680abc881873073943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - pathology</topic><topic>Autoimmune disorders</topic><topic>Autoimmune myelofibrosis</topic><topic>Bone marrow</topic><topic>Bone marrow fibrosis</topic><topic>Disease</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>IgG4 related disease</topic><topic>Immune system</topic><topic>Lupus</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metabolic disorders</topic><topic>Middle Aged</topic><topic>Morphologic criteria</topic><topic>Non-neoplastic fibrosis</topic><topic>Pathology</topic><topic>Primary Myelofibrosis - pathology</topic><topic>Transplants &amp; implants</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vergara-Lluri, Maria E., MD</creatorcontrib><creatorcontrib>Piatek, Caroline I., MD</creatorcontrib><creatorcontrib>Pullarkat, Vinod, MD</creatorcontrib><creatorcontrib>Siddiqi, Imran N., MD, PhD</creatorcontrib><creatorcontrib>O'Connell, Casey, MD</creatorcontrib><creatorcontrib>Feinstein, Donald I., MD</creatorcontrib><creatorcontrib>Brynes, Russell K., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vergara-Lluri, Maria E., MD</au><au>Piatek, Caroline I., MD</au><au>Pullarkat, Vinod, MD</au><au>Siddiqi, Imran N., MD, PhD</au><au>O'Connell, Casey, MD</au><au>Feinstein, Donald I., MD</au><au>Brynes, Russell K., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>45</volume><issue>11</issue><spage>2183</spage><epage>2191</epage><pages>2183-2191</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>Summary Autoimmune myelofibrosis (AIMF) is a distinct clinicopathological entity associated with diffuse bone marrow fibrosis and a benign clinical course. Distinction from neoplastic etiologies of marrow fibrosis, particularly primary myelofibrosis, is imperative, but few studies have documented histopathologic features in a large series. We describe 29 patients with AIMF, defined as marrow reticulin fibrosis and lymphocytic infiltration in the context of an established autoimmune disorder (secondary AIMF) or autoantibodies without a defined disorder (primary AIMF). Excluded were cases with atypical megakaryocytes, dysplasia, basophilia, osteosclerosis, unexplained splenomegaly, or neoplasms associated with myelofibrosis (MF). All cases were stained for reticulin, CD3, and CD20, with a subset additionally stained for CD138, κ , λ , immunoglobulin G (IgG), and IgG4. Lymphoid aggregates, where present, were classified into T-cell and B-cell patterns of distribution. Most patients (93%) presented with cytopenias. Sixty-nine percent (n = 20) were considered secondary AIMF and the remainder primary AIMF (n = 9). Peripheral blood showed absent-to-rare blasts and teardrop erythrocytes and absence of eosinophilia or basophilia. Characteristic bone marrow findings included hypercellularity with erythroid and megakaryocytic hyperplasias, mild reticulin fibrosis, intrasinusoidal hematopoiesis, T-cell pattern in lymphoid aggregates, mild polytypic plasmacytosis, and absence of IgG4-positive plasma cells. Primary and secondary AIMF were pathologically indistinguishable, except for an increased incidence of granulocytic hyperplasia in primary AIMF. This series confirms and expands the utility of the original diagnostic criteria for AIMF. Recognizing the characteristic morphology of AIMF and its associated clinical and laboratory features distinguishes autoimmune from neoplastic causes of MF and guides further evaluation and management.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25282037</pmid><doi>10.1016/j.humpath.2014.07.017</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2014-11, Vol.45 (11), p.2183-2191
issn 0046-8177
1532-8392
language eng
recordid cdi_proquest_miscellaneous_1654670894
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult
Aged
Autoimmune diseases
Autoimmune Diseases - pathology
Autoimmune disorders
Autoimmune myelofibrosis
Bone marrow
Bone marrow fibrosis
Disease
Female
Hepatitis
Humans
IgG4 related disease
Immune system
Lupus
Lymphocytes
Male
Medical prognosis
Metabolic disorders
Middle Aged
Morphologic criteria
Non-neoplastic fibrosis
Pathology
Primary Myelofibrosis - pathology
Transplants & implants
Tumors
Young Adult
title Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A10%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoimmune%20myelofibrosis:%20an%20update%20on%20morphologic%20features%20in%2029%20cases%20and%20review%20of%20the%20literature&rft.jtitle=Human%20pathology&rft.au=Vergara-Lluri,%20Maria%20E.,%20MD&rft.date=2014-11-01&rft.volume=45&rft.issue=11&rft.spage=2183&rft.epage=2191&rft.pages=2183-2191&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2014.07.017&rft_dat=%3Cproquest_cross%3E1654670894%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1614920115&rft_id=info:pmid/25282037&rft_els_id=1_s2_0_S0046817714003153&rfr_iscdi=true